An announcement from Ibio Inc (IBIO) is now available.
iBio, Inc. has successfully sold its PD-1 agonist assets to Otsuka Pharmaceutical for an initial $1 million, with additional payments of up to $52.5 million tied to future development and commercial milestones. Originally acquired from RubrYc Therapeutics, these assets are part of a strategic move, with iBio focusing on its patented AI drug discovery platform and other immuno-oncology candidates. Details of the transaction, which do not affect other developmental milestones from the RubrYc agreement, were made public in a press release on February 26, 2024.
For a thorough assessment of IBIO stock, go to TipRanks’ Stock Analysis page.
